News

Reverdia starts its bio-succinic acid plant
Enlarge image

BusinessItalyNetherlandsFrance

Reverdia starts its bio-succinic acid plant

17.12.2012 - Reverdia has started industrial production of bio-succinic acid at a new production plant with an annual capacity of 10,000 metric tons.

The joint venture between Dutch DSM NV and French starch producer Roquette Frères has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium™ sustainable succinic acid. The company said the plant, which has a capacity of about 10,000 tonnes/yr, was unique in its kind, being the world’s first dedicated large-scale plant for the production of succinic acid from renewable resources. However, according to US-based BioAmber Inc, which fused BioAmber SAS and US company DNP Green Technology in 2010, it has been producing the chemical building block at 4,000 tonnes/yr since 2009.

Both producers rely on genetically engineered E.coli strains for producing the compound, that is being used to make bioplastics, chemical internmediates such as 1,4 butanediol, solvents, coatings, and phthalate-free plasticisers. As the market for bio-based succinic acid is expected to grow rapidly in the next few years, other joint-ventures such as Succinity or US-based Myriant Inc. are building production facilities. Reverdia will market its bio-succinium in collaboration with Helm.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-starts-its-bio-succinic-acid-plant.html

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • RENEURON (UK)3.50 GBP7.69%

FLOP

  • KAROLINSKA (S)8.00 SEK-8.05%
  • NOVACYT (F)1.50 EUR-7.98%
  • UCB (B)62.79 EUR-7.55%

TOP

  • GENMAB (DK)1229.00 DKK28.0%
  • NICOX (F)10.97 EUR27.7%
  • GALAPAGOS (B)50.94 EUR26.4%

FLOP

  • BIONOR PHARMA (N)0.69 NOK-24.2%
  • BIOCARTIS GROUP NV (B)8.20 EUR-24.1%
  • MOBERG PHARMA (S)38.40 SEK-23.6%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.20 SEK1900.0%
  • NICOX (F)10.97 EUR486.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-87.1%
  • BB BIOTECH (D)44.27 EUR-84.4%
  • BIOTEST (D)16.90 EUR-77.8%

No liability assumed, Date: 25.05.2016